Aclysiran, an RNAi therapeutic agent targeting ACLY, treats hypercholesterolemia and atherosclerosis in ApoE–/– mice
Meijie Chen,
Peter J. Little,
Sudong Kong,
Maciej Banach,
Jianping Weng,
Suowen Xu
Affiliations
Meijie Chen
Department of Endocrinology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Anhui Provincial Key Laboratory of Metabolic Health and Panvascular Diseases, Hefei 230001, China
Peter J. Little
Department of Pharmacy, Guangzhou Xinhua University, Guangzhou 510520, China
Sudong Kong
Suzhou Biosyntech Co., Ltd., Suzhou 215300, China
Maciej Banach
Department of Preventive Cardiology and Lipidology, Medical University of Lodz 23 (MUL), Lodz 93-338, Poland; Corresponding authors.
Jianping Weng
Department of Endocrinology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Anhui Provincial Key Laboratory of Metabolic Health and Panvascular Diseases, Hefei 230001, China; Corresponding authors.
Suowen Xu
Department of Endocrinology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Anhui Provincial Key Laboratory of Metabolic Health and Panvascular Diseases, Hefei 230001, China; Corresponding authors.
